Clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators for arrhythmias: A systematic review and economic evaluation

International Journal of Technology Assessment in Health Care

Volumn 23, Issue 1, 2007, Pages 63-70

  Bryant, Jackie ^a   Brodin, Hakan ^a   Loveman, Emma ^a   Clegg, Andrew ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Antiarrhythmia agents; Arrhythmia; Heart arrest; Implantable cardioverter defibrillator

Indexed keywords

COST EFFECTIVENESS; DECISION MAKING; ECONOMIC ANALYSIS; HEALTH CARE; MATHEMATICAL MODELS; QUALITY ASSURANCE; RISK ASSESSMENT;

ANTIARRHYTHMIA AGENTS; ARRHYTHMIA; DATA EXTRACTION; HEART ARREST; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR;

MEDICAL PROBLEMS;

AMIODARONE; ANTIARRHYTHMIC AGENT;

BLEEDING; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DECISION MAKING; DEFIBRILLATOR; HEALTH CARE COST; HEART ARRHYTHMIA; HEMATOMA; HIGH RISK POPULATION; HUMAN; INFECTION; MEDICAL LITERATURE; METHODOLOGY; MORTALITY; PLEURA EFFUSION; PNEUMOTHORAX; PROSTHESIS FAILURE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SUDDEN DEATH; SYSTEMATIC REVIEW; UNITED KINGDOM;

ARRHYTHMIA; COST-BENEFIT ANALYSIS; DEFIBRILLATORS, IMPLANTABLE; HUMANS; TREATMENT OUTCOME;

EID: 34247487949     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462307051586     Document Type: Review

References (45)

1. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576-1583.
2. Anonymous. State-specific mortality from sudden cardiac death - US 1999. MMWR Morb Mortal Wkly Rep. 2002;51:123-126.
3. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: The Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453-1458.
4. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.
5. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569-1575.
6. Bristow MR, Saxon LA, Boehmer J. Cardiac resynchronisation therapy with or without an implantable cardioverter defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
7. Bryant J, Brodin H, Loveman E, et al. The clinical effectiveness and cost effectiveness of implantable cardioverter defibrillators: Arrhythmias. Health Technol Assess. 2005;9:36.
8. Buxton AE, Lee KL, Fisher JD. A randomized study of the prevention of sudden cardiac death in patients with coronary artery disease. N Engl J Med. 1999;341:1882-1890.
9. Buxton MJ, Caine N, Chase D, et al. A review of the evidence on the effects and costs of implantable cardiac defibrillators (ICD) therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context (project number 99/23/04). Health Technol Assess. In press.
10. Connolly SJ, Gent M, Roberts RS. Canadian Implantable Defibrillator Study (CIDS) A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297-1302.
11. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator Study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071-2078.
12. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Out-of-hospital cardiac arrest in the 1990's: A population-based study in the Maastrict area on incidence, characteristics and survival. J Am Coll Cardiol. 1997;30:1500-1505.
13. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275-283.
14. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: A systematic review of randomized, controlled trials. Ann Intern Med. 2003;138:445-452.
15. Hlatky M. Evidence-based use of cardiac procedures and devices. N Engl J Med. 2004;350:2126-2128.
16. http://www.nice.org.uk/pdf/Arrhythmias FAD.pdf. Accessed January 10, 2006.
17. Irvine J, Dorian P, Baker B, et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J. 2002;144:282-289.
18. Jadad AR, Moore A, Carroll D. Assessing the quality of reports of randomised clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1-12.
19. Joint Submission to NICE by ABHI CRM Special Interest Section (Biotronik, ELA, Guidant, Medtronic, St Jude). October 2003.
20. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158.
21. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-754.
22. Kupersmith J, Hogan A, Guerrero P, et al. Evaluating and improving the cost-effectiveness of the implantable cardioverter-defibrillator. Am Heart J. 1995;130(Pt 1):507-515.
23. Kuppermann M, Luce BR, McGovern B. An analysis of the cost effectiveness of the implantable defibrillator. Circulation. 1990;81:91-100.
24. Larsen G, Hallstrom A, McAnulty J, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: Results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation. 2002;105:2049-2057.
25. Larsen GC, Manolis AS, Sonnenberg FA, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: Effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol. 1992;19:1323-1334.
26. Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: A meta-analysis. J Am Coll Cardiol. 2003;41:1573-1582.
27. Moss AJ, Fadl Y, Zareba W, et al. Defibrillator Implantation Trial Research Group. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol. 2001;88:516-520.
28. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-1940.
29. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
30. Mushlin AI. The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT. Circulation. 1998;25:2129-2135.
31. Namerow PB, Firth BR, Heywood GM, et al. Quality-of-life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: Findings from the CABG Patch Trial. Pacing Clin Electrophysiol. 1999;22:1305-1313.
32. National Institute for Clinical Excellence. Guidance on the use of implantable cardioverter defibrillators for arrhythmias. London: National Institute for Clinical Excellence (NICE); 2000.
33. National Statistics. Mortality statistics: Cause. Review of the Registrar General on deaths by cause, sex and age in England and Wales in 2001. London: Office for National Statistics; 2002. No. DH2 no. 28.
34. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD guidelines for those carrying out or commissioning reviews. 1999. No. CRD Report 4.
35. O'Brien BJ, Buxton MJ, Ruskin JN. Cost effectiveness of the implantable cardioverter-defibrillator: A preliminary analysis. Br Heart J. 1992;68:241-245.
36. O'Brien BJ, Connolly SJ, Goeree R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: Results from the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2001;103:1416-1421.
37. O'Brien BJ, Heyland D, Richardson WS, et al. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. B. What are the results andwill they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA. 1997;277:1802-1806.
38. Owens DK, Sanders GD, Harris RA, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med. 1997;126:1-12.
39. Owens DK, Sanders GD, Heidenreich PA, et al. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J. 2002;144:440-448.
40. Sanders GD, Hlatky MA, Every NR, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med. 2001;135:870-883.
41. Schilling RJ, Kaye G. Epidemiology and management of failed sudden cardiac death. Hosp Med. 1998;59:116-119.
42. Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: Impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002;105:589-594.
43. Seidl K, Senges J. Worldwide utilisation of implantable cardioverter defibrillators now and in the future. Card Electrophysiol Rev. 2003;7:5-13.
44. Technology Evaluation Center. Special report: Cost-effectiveness of implantable cardioverter-defibrillators in a MADIT-II population. Technol Eval Cent Asses Program Exec Summ. 2004;19:1-2.
45. Wever EF, Hauer RN, Schwetz KM. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors. Circulation. 1996;93:489-496.